Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets
Pathology - Research and Practice · 2025-11 · 275 · 156245
DOI: 10.1016/j.prp.2025.156245 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2025-11. Verfasst von Kamini R Shirasath und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule, Maharashtra 424001, India. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 347 Literaturangaben. Gefördert von: Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy, Central Council for Research in Unani Medicine, Government of India Ministry of Ayush.
Abstract (Originalsprache)
Polycystic ovary syndrome (PCOS) is a common health problem that can affect the reproductive health of women. A typical characteristic of PCOS is infertility, androgen excess, and anovulation. In addition, a disorder also accompanies other pathologies like obesity and hyperinsulinemia, with an increased threat of cardiovascular complications. Current treatment strategies focus on the reduction of PCOS symptoms primarily through pharmacological medications such as metformin, oral contraceptives, and anti-androgenic agents. Since these medications do not encompass all the outcomes of PCOS, there is a critical need for research to identify more effective treatments. Given the rising global prevalence of PCOS and its association with cardiovascular and metabolic risks, there is an urgent need for better therapeutic options with minimal adverse effects. This review integrates the current pharmacotherapies and emerging molecular and cellular targets, offering novel directions for comprehensive PCOS management. Additionally, this review explores various novel targets such as neuropeptides, inflammasome, anti-inflammatory agents, gene therapy/microRNA (miRNA) based therapies, adipokines-based therapies and stem cells-based therapy. Furthermore, we highlight key areas requiring further research to improve PCOS management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule, Maharashtra 424001, India.
- Central Council for Research in Unani Medicine (CCRUM), New Delhi 110058, India.
- Regional Research Institute of Unani Medicine (RRIUM), Kharghar, Navi Mumbai, India.
- Department of Pharmaceutics, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule, Maharashtra 424001, India. Electronic address: yogeeta.goyal@svkm.ac.in.
Förderung
- Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy
- Central Council for Research in Unani Medicine
- Government of India Ministry of Ayush
Zitieren
APA
Shirasath, K. R., Ahmed, N. Z., Kumar, P., Alam, S., Karwasra, R., Goyal, S. N., & Agrawal, Y. O. (2025). Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets. Pathology - Research and Practice, 275, 156245. https://doi.org/10.1016/j.prp.2025.156245
Vancouver
Shirasath KR, Ahmed NZ, Kumar P, Alam S, Karwasra R, Goyal SN, et al. Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets. Pathology - Research and Practice. 2025;275:156245. doi:10.1016/j.prp.2025.156245
BibTeX
@article{Shirasath2025,
author = {Shirasath, Kamini R and Ahmed, N Zaheer and Kumar, Pawan and Alam, Shah and Karwasra, Ritu and Goyal, Sameer N and Agrawal, Yogeeta O},
title = {Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets},
journal = {Pathology - Research and Practice},
year = {2025},
volume = {275},
pages = {156245},
doi = {10.1016/j.prp.2025.156245}
}
EUVIMED